Browse in-depth TOC on " Global Biotechnology industry Outlook " 10 - Tables 20 - Figures 70 - Pages . The Global Biotech ...

Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that ...

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

The industry continues to face financial and regulatory headwinds, including high interest rates and uncertainty about ...

Initial rounds of VC financing totaled $7.7 billion over 137 deals for biopharma in 2024, compared to $3.8 billion over 156 ...

Collectively, as well as independently, the firms represent generations of commercial real estate experience and family ...

This double-digit growth in new drug sales showcases the company's ability to successfully commercialize cutting-edge ...

The Biden administration’s justification of the first cycle of Medicare drug price negotiations is fueling curiosity and ...

International Assets Investment Management LLC cut its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 98.4% ...

The stock's fall snapped a two-day winning streak.

The UK's self-regulated system for disclosing payments from drug companies to health care professionals and organizations is ...